Coadyuvantes en el tratamiento de la esquizofrenia

Abstract

Introduction Schizophrenia is a global public health problem, affecting approximately 1% of the world's population. Some treatments sometimes do not compensate for the disease, since the side effects are very noticeable after administration. Nowadays, studies reveal that quetiapine and risperidone contribute to treatment to improve the disease and condition of patients. General objective

To describe the efficacy of quetiapine and risperidone as adjuvant treatments for schizophrenia in adults, through a narrative literature review of systematic reviews, meta- analyses, and general reviews published between 2019 and 2024. Methodology This research is based on a narrative literature review to evaluate the efficacy of quetiapine and risperidone as adjuvant treatments in adults with schizophrenia. Studies published between 2019 and 2024 in English are included, restricted to systematic reviews, meta- analyses, and general reviews. The search was conducted in high-impact databases such as Scopus, PubMed, Web of Science, Ovid, Springer Link, and Cochrane Library, using MeSH terms such as “schizophrenia,” “quetiapine,” “fumarate” and “risperidone,” combined with Boolean operators optimizing the retrieval of relevant information. The selected articles were evaluated according to the specific objectives. Results obtained

The results show that quetiapine improves cognitive symptoms with side effects such as sedation, while risperidone is effective in positive and negative symptoms, but can cause sexual dysfunction. Both medications offer effective and adaptable options for the complementary treatment of schizophrenia.